Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Prodrugs for targeted cancer therapy

Texto completo
Autor(es):
Souza, Carla [1] ; Pellosi, Diogo Silva [2] ; Tedesco, Antonio Claudio [1]
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Philosophy Sci & Letters Ribeirao Preto, Dept Chem, Ctr Nanotechnol & Tissue Engn, Ribeirao Preto - Brazil
[2] Univ Fed Sao Paulo, UNIFESP, Lab Hybrid Mat, Dept Chem, Diadema - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo de Revisão
Fonte: EXPERT REVIEW OF ANTICANCER THERAPY; v. 19, n. 6, p. 483-502, JUN 3 2019.
Citações Web of Science: 0
Resumo

Introduction: Prodrugs have been used to improve the selectivity and efficacy of cancer therapy by targeting unique abnormal markers that are overexpressed by cancer cells and are absent in normal tissues. In this context, different strategies have been exploited and new ones are being developed each year.Areas covered: In this review, an integrated view of the potential use of prodrugs in targeted cancer therapy is provided. Passive and active strategies are discussed in light of the advantages of each one and some successful examples are provided, as well as the clinical status of several prodrugs. Among them, antibody-drug conjugates (ADCs) are the most commonly used. However, several drawbacks, including limited prodrug uptake, poor pharmacokinetics, immunogenicity problems, difficulties in selective targeting and gene expression, and optimized bystander effects limit their clinical applications. Expert opinion: Despite the efforts of different companies and research groups, several drawbacks, such as the lack of relevant in vivo models, complexity of the human metabolism, and economic limitations, have hampered the development of new prodrugs for targeted cancer therapy. As a result, we believe that the combination of prodrugs with cancer nanotechnology and other newly developed approaches, such as aptamer-conjugated nanomaterials, are efficient strategies. (AU)

Processo FAPESP: 16/00389-3 - Nanopartículas multifuncionais para a entrega sítio-específica da temozolomida e verteporfina para a terapia combinada de tumores cerebrais
Beneficiário:Diogo Silva Pellosi
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 17/01272-5 - Modelos in vitro de pele reconstituída: desenvolvimento, avaliação dos danos e da eficácia fotoprotetora nas regiões uva e visível do espectro solar
Beneficiário:Carla Souza
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 13/50181-1 - Utilização de nanocarreadores contendo fármacos fotossensibilizantes e outros ativos aplicados à terapia celular e tratamento de patologias do sistema nervoso central
Beneficiário:Antonio Claudio Tedesco
Linha de fomento: Auxílio à Pesquisa - Temático